机构：[1]Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China[2]Rational Medication Evaluation and DrugDelivery Technology Lab, Nanfang Hospital, Southern Medical University, Guangzhou, China[3]Modern Chinese Medicine Institute, HutchisonWhampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, Guangzhou, China[4]Office of the General Manager, HutchisonWhampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, Guangzhou, China[5]Guangdong Key Laboratory of New DrugScreening, Southern Medical University, Guangzhou, China
Xinmai 'an tablet has been used to improve myocardial blood supply. Recently, some compounds from its formula have shown that they can treat pulmonary arterial hypertension (PAH).
This study investigates the effects of Xinmai 'an extract (XMA) on PAH and further tests the co-therapeutic enhancement with sildenafil (SIL).
Pulmonary artery smooth muscle cells were subjected to stimulation with SIL (12.5 μM) and XMA (250 μg/mL) for 48 h. Sprague-Dawley rats were randomly grouped into eight groups (n = 8 per group): (I) control group received saline; (II) MCT group received MCT (60 mg/kg); (III) SIL-Low group received MCT + SIL at 10 mg/kg/day; (IV) SIL-high group received MCT + SIL at 30 mg/kg/day; (V) XMA-High group received MCT + XMA at 251.6 mg/kg/day; (VI) SIL (Low)+XMA (Low) group received SIL (10 mg/kg) + XMA at 62.9 mg/kg/day; (VII) SIL (Low)+XMA (Medium) group received SIL (10 mg/kg) + XMA at 125.8 mg/kg/day; (VIII) SIL (Low)+XMA (High) group received SIL (10 mg/kg) + XMA at 251.6 mg/kg/day. Both XMA and SIL were given by gavage and were maintained daily for 2 weeks.
XMA could improve SIL's efficacy in the treatment of PAH by decreasing cell viability more effectively at non-cytotoxic concentrations (250 μg/mL) and reducing Right Ventricular Systolic Pressure (RVSP) in PAH rat. Potential mechanisms might at least in part be through activating the MAPK signalling pathway.
The combination of XMA and SIL can improve the efficacy of pulmonary hypertension and reduce the dosage of SIL.
基金：
This work was supported by a grant from Pearl River S&T Nova
Program of Guangzhou [20180601006].
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|3 区医学
小类|3 区医学实验技术3 区药学3 区植物科学
最新[2025]版：
大类|3 区医学
小类|2 区医学实验技术2 区药学2 区植物科学
第一作者：
第一作者机构：[1]Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China[2]Rational Medication Evaluation and DrugDelivery Technology Lab, Nanfang Hospital, Southern Medical University, Guangzhou, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China[2]Rational Medication Evaluation and DrugDelivery Technology Lab, Nanfang Hospital, Southern Medical University, Guangzhou, China[5]Guangdong Key Laboratory of New DrugScreening, Southern Medical University, Guangzhou, China[*1]Department of Pharmacy, Nanfang Hospital, Southern Medical University, No.1023, South Shatai Road, Baiyun District, Guangzhou 510515, China
推荐引用方式(GB/T 7714)：
Zhu Yaolu,Sun Yabin,Zhang Shichang,et al.Xinmai 'an extract enhances the efficacy of sildenafil in the treatment of pulmonary arterial hypertension via inhibiting MAPK signalling pathway.[J].Pharmaceutical biology.2021,59(1):594-605.doi:10.1080/13880209.2021.1917629.
APA：
Zhu Yaolu,Sun Yabin,Zhang Shichang,Li Chuyuan,Zhao Yiwei...&Li Guofeng.(2021).Xinmai 'an extract enhances the efficacy of sildenafil in the treatment of pulmonary arterial hypertension via inhibiting MAPK signalling pathway..Pharmaceutical biology,59,(1)
MLA：
Zhu Yaolu,et al."Xinmai 'an extract enhances the efficacy of sildenafil in the treatment of pulmonary arterial hypertension via inhibiting MAPK signalling pathway.".Pharmaceutical biology 59..1(2021):594-605
